EGFR and non-small cell lung carcinoma: Treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been the first-line treatment for NSCLC patients who harbour activating EGFR mutations, however, often acquired resistance to EGFR TKIs, which is common within 12 months of treatment, mostly due to the T790M mutation detected in approximately 60% of patients (Rosell et al. 2012; Cortot and Janne 2014; Sacher et al. 2014).